Overview

* Biodesix Q3 2025 revenue grows 20% yr/yr, beating analyst expectations

* Company raises FY2025 revenue guidance to $84-86 mln

* Gross profit margin improves by 400 basis points yr/yr

Outlook

* Biodesix ( BDSX ) raises FY2025 revenue guidance to $84-86 mln

* Company expects Adjusted EBITDA positivity in Q4 2025

* Biodesix ( BDSX ) sees sustainable long-term growth in lung disease diagnostics

Result Drivers

* PRIMARY CARE EXPANSION - Strategic expansion into primary care contributed to increased lung diagnostic tests and revenue growth

* DEVELOPMENT SERVICES GROWTH - Development Services business saw 97% yr/yr revenue growth, driven by contracted business and new agreements

* LUNG DIAGNOSTIC TESTING - Increase in lung diagnostic testing volumes and average revenue per test boosted revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $21.80 $20.97

Revenue mln mln (5

Analysts

)

Q3 EPS -$1.16

Q3 Net -$8.70

Income mln

Q3 $24.70

Adjusted mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Biodesix Inc ( BDSX ) is $35.00, about 80.5% above its October 31 closing price of $6.83

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)